Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/35252

Type
Article
Copyright
Restricted access
Embargo date
2025-01-01
Sustainable Development Goals
03 Saúde e Bem-Estar
Collections
Share

Statistics
Metadata
Show full item record

DRUG DISCOVERY FOR KINETOPLASTID DISEASES: FUTURE DIRECTIONS
Rao, Srinivasa P. S. et al. | Date Issued: 2019
Author
Rao, Srinivasa P. S.
Barrett, Michael P.
Dranoff, Glenn
Faraday, Christopher J.
Gimpelewicz, Claudio R.
Hailu, Asrat
Jones, Catherine L.
Kelly, John M.
Lazdins-Helds, Janis K.
Mäser, Pascal
Mengel, Jose
Mottram, Jeremy C.
Mowbray, Charles E.
Sacks, David L.
Scott, Phillip
Späth, Gerald F.
Tarleton, Rick L.
Spector, Jonathan M.
Diagana, Thierry T.
Affilliation
Novartis Institute for Tropical Diseases. Emeryville, California, USA.
University of Glasgow. University Place, Glasgow. United Kingdom.
Novartis Institutes for Biomedical Research. Immuno-oncology, Cambridge, Massachusetts, USA.
Autoimmunity Transplantation and Inflammation NIBR. Basel, Switzerland.
Global Drug Development. Novartis Pharma. Forum 1. Basel, Switzerland.
Addis Ababa University. School of Medicine. Addis Abeba, Ethiopia.
Novartis Institute for Tropical Diseases. Emeryville, California, USA.
London School of Hygiene and Tropical Medicine. London, United Kingdom.
Independent Consultant. Geneva, Switzerland.
Swiss Tropical and Public Health Institute. Basel, Switzerland / University of Basel. Basel, Switzerland.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Clínica. Rio de Janeiro, RJ, Brasil / Faculdade de Medicina de Petrópolis. Petrópolis, RJ, Brasil.
University of York. Wentworth Way Heslington. York, United Kingdom.
Drugs for Neglected Diseases initiative. Geneva, Switzerland.
National Institute of Allergy and Infectious Diseases; Bethesda, Maryland, USA.
University of Pennsylvania. Phyladelphia, Pennsylvania, USA.
Institut Pasteur. Paris, France.
University of Georgia; Athens,Georgia, USA.
Novartis Institute for Tropical Diseases. Emeryville, California, USA.
Novartis Institute for Tropical Diseases. Emeryville, California, USA.
Abstract
Kinetoplastid parasites have caused human disease for millennia. Significant achievements have been made toward developing new treatments for leishmaniasis (particularly on the Indian subcontinent) and for human African trypanosomiasis (HAT). Moreover, the sustained decrease in the incidence of HAT has made the prospect of elimination a tantalizing reality. Despite the gains, no new chemical or biological entities to treat kinetoplastid diseases have been registered in more than three decades, and more work is needed to discover safe and effective therapies for patients with Chagas disease and leishmaniasis. Advances in tools for drug discovery and novel insights into the biology of the host-parasite interaction may provide opportunities for accelerated progress. Here, we summarize the output from a gathering of scientists and physicians who met to discuss the current status and future directions in drug discovery for kinetoplastid diseases.
Keywords in Portuguese
Tripanossomose africana humana
Parasitas
Doença de Chagas
Leishmaniose
Novos medicamentos
Cinetoplastid
 
Keywords
Kinetoplastid
Drug Discover
Parasites
Leishmaniasis
Human African trypanosomiasis
 
Publisher
American Chemical Society
Citation
RAO, Srinivasa P. S. et al. Drug Discovery for Kinetoplastid Diseases: Future Directions. ACS Infectious Diseases, v. 5, p. 152-157, 2019.
DOI
10.1021/acsinfecdis.8b00298
ISSN
2373-8227